Dermata Therapeutics Inc (DRMA)

$4.01 -0.17 (-4.02%)
Market Cap 2.85M
Revenue (ttm) 0.00
Net Income (ttm) -12.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 84,600
Avg Vol 162,606
Day's Range N/A - N/A
Shares Out 682,000.00
Stochastic %K 18%
Beta 0.56
Analysts Strong Sell
Price Target $10.00

Company Profile

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 800 2543
Address:
3525 Del Mar Heights Rd., Suite 332, San Diego, United States
invinc1ble
invinc1ble Oct. 25 at 4:00 PM
$DRMA can 100% and shock you
0 · Reply
Bubbasoup09
Bubbasoup09 Oct. 24 at 12:30 AM
$DRMA bunch of DRMA queens
0 · Reply
Mau74
Mau74 Oct. 23 at 9:52 PM
$DRMA what a piece of shit. I don’t know when i’ll go out from this shit
0 · Reply
Hd88sport
Hd88sport Oct. 23 at 9:48 PM
$DRMA thought we had a runner...
0 · Reply
youngpennytwits
youngpennytwits Oct. 23 at 9:48 PM
$DRMA go to 12 on Warrants u pos
0 · Reply
youngpennytwits
youngpennytwits Oct. 23 at 9:45 PM
$DRMA 4.85 to 4.10 wtf u pos
0 · Reply
Pinarello
Pinarello Oct. 23 at 9:38 PM
$DRMA Funny Seems like a last breath
0 · Reply
youngpennytwits
youngpennytwits Oct. 23 at 9:34 PM
$DRMA pos
0 · Reply
Hd88sport
Hd88sport Oct. 23 at 9:22 PM
$DRMA
0 · Reply
Pinarello
Pinarello Oct. 23 at 9:18 PM
$DRMA Live ?
0 · Reply
Latest News on DRMA
Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office

Oct 2, 2025, 8:00 AM EDT - 23 days ago

Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office

Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

Sep 17, 2025, 1:00 AM EDT - 5 weeks ago

Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th

Sep 16, 2025, 8:35 AM EDT - 5 weeks ago

Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th

Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments

Sep 10, 2025, 8:00 AM EDT - 6 weeks ago

Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 5:00 PM EDT - 2 months ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

Jul 8, 2025, 8:00 AM EDT - 3 months ago

Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 14, 2025, 9:00 AM EDT - 5 months ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

Apr 15, 2025, 8:30 AM EDT - 6 months ago

Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Mar 27, 2025, 8:15 PM EDT - 7 months ago

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne

Mar 27, 2025, 10:21 AM EDT - 7 months ago

Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne

Dermata Therapeutics Shares Surge on Positive Acne Treatment Study

Mar 27, 2025, 9:57 AM EDT - 7 months ago

Dermata Therapeutics Shares Surge on Positive Acne Treatment Study

BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

Mar 27, 2025, 8:00 AM EDT - 7 months ago

BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

Mar 17, 2025, 4:16 PM EDT - 7 months ago

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

Mar 4, 2025, 8:03 AM EST - 8 months ago

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

Feb 25, 2025, 7:58 AM EST - 8 months ago

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

Dermata to Present on BioPub on January 31, 2025

Jan 29, 2025, 4:05 PM EST - 9 months ago

Dermata to Present on BioPub on January 31, 2025

Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment

Jan 28, 2025, 4:05 PM EST - 9 months ago

Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment

Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 23, 2025, 4:15 PM EST - 9 months ago

Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 22, 2025, 8:00 AM EST - 9 months ago

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

Jan 21, 2025, 8:00 AM EST - 9 months ago

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

Dec 16, 2024, 9:00 AM EST - 11 months ago

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

Dec 10, 2024, 9:00 AM EST - 11 months ago

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dec 3, 2024, 9:00 AM EST - 11 months ago

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Nov 13, 2024, 4:15 PM EST - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

Nov 11, 2024, 8:35 AM EST - 1 year ago

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024

Oct 8, 2024, 4:15 PM EDT - 1 year ago

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 17, 2024, 5:15 PM EDT - 1 year ago

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 16, 2024, 9:00 PM EDT - 1 year ago

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Jul 17, 2024, 9:00 AM EDT - 1 year ago

Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

May 17, 2024, 8:30 AM EDT - 1 year ago

Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 15, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Dermata to Present at the Emerging Growth Conference on April 3, 2024

Mar 27, 2024, 4:05 PM EDT - 1 year ago

Dermata to Present at the Emerging Growth Conference on April 3, 2024

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results

Mar 21, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results

Dermata to Present at the Emerging Growth Conference on February 7, 2024

Feb 1, 2024, 9:00 AM EST - 1 year ago

Dermata to Present at the Emerging Growth Conference on February 7, 2024

Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis

Jan 4, 2024, 4:05 PM EST - 1 year ago

Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis

Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dec 20, 2023, 4:05 PM EST - 2 years ago

Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Nov 16, 2023, 1:30 PM EST - 2 years ago

Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols

Nov 16, 2023, 8:00 AM EST - 2 years ago

Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Nov 9, 2023, 4:05 PM EST - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Dermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trial

Oct 26, 2023, 9:00 AM EDT - 2 years ago

Dermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trial

Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 31, 2023, 9:00 AM EDT - 2 years ago

Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Aug 10, 2023, 4:15 PM EDT - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne

Jun 27, 2023, 9:00 AM EDT - 2 years ago

Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne

Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

Jun 13, 2023, 4:15 PM EDT - 2 years ago

Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results

Jun 8, 2023, 9:00 AM EDT - 2 years ago

Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results

Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules

May 26, 2023, 4:00 PM EDT - 2 years ago

Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules

May 24, 2023, 8:00 AM EDT - 2 years ago

Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 11, 2023, 4:05 PM EDT - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

invinc1ble
invinc1ble Oct. 25 at 4:00 PM
$DRMA can 100% and shock you
0 · Reply
Bubbasoup09
Bubbasoup09 Oct. 24 at 12:30 AM
$DRMA bunch of DRMA queens
0 · Reply
Mau74
Mau74 Oct. 23 at 9:52 PM
$DRMA what a piece of shit. I don’t know when i’ll go out from this shit
0 · Reply
Hd88sport
Hd88sport Oct. 23 at 9:48 PM
$DRMA thought we had a runner...
0 · Reply
youngpennytwits
youngpennytwits Oct. 23 at 9:48 PM
$DRMA go to 12 on Warrants u pos
0 · Reply
youngpennytwits
youngpennytwits Oct. 23 at 9:45 PM
$DRMA 4.85 to 4.10 wtf u pos
0 · Reply
Pinarello
Pinarello Oct. 23 at 9:38 PM
$DRMA Funny Seems like a last breath
0 · Reply
youngpennytwits
youngpennytwits Oct. 23 at 9:34 PM
$DRMA pos
0 · Reply
Hd88sport
Hd88sport Oct. 23 at 9:22 PM
$DRMA
0 · Reply
Pinarello
Pinarello Oct. 23 at 9:18 PM
$DRMA Live ?
0 · Reply
MrTicker
MrTicker Oct. 23 at 9:16 PM
$DRMA seeing some volume after hours, tapping the scanner.. keep an eye on this
0 · Reply
Idiotinvestur
Idiotinvestur Oct. 23 at 7:58 PM
$DRMA say the word….crypto
0 · Reply
biggmtbtrades
biggmtbtrades Oct. 22 at 10:01 PM
$DRMA something in my gut is telling me that this is just about ready to take off
1 · Reply
youngpennytwits
youngpennytwits Oct. 21 at 6:37 PM
$DRMA blow it to 14
0 · Reply
Hd88sport
Hd88sport Oct. 21 at 4:18 PM
$DRMA any upcoming news?
0 · Reply
biggmtbtrades
biggmtbtrades Oct. 21 at 12:11 PM
$DRMA Set to go any day now…it’s primed
0 · Reply
youngpennytwits
youngpennytwits Oct. 20 at 11:19 PM
$DRMA squeeze u sob
0 · Reply
Bookshelf1974
Bookshelf1974 Oct. 20 at 9:37 PM
$DRMA low float, low os, tic tic tic tic.....
0 · Reply
davidscr
davidscr Oct. 20 at 7:28 PM
$DRMA @Unalloyed What does that mean? Can you explain it to me? Thanks.
0 · Reply
davidscr
davidscr Oct. 20 at 7:27 PM
$DRMA @Unalloyed What does that mean? Can you explain it to me? Thanks.
0 · Reply
youngpennytwits
youngpennytwits Oct. 20 at 6:19 PM
$DRMA send this pic to 12
0 · Reply
Unalloyed
Unalloyed Oct. 20 at 11:43 AM
$DRMA January warrants haven't exercised yet. Approved in July. https://www.sec.gov/Archives/edgar/data/1853816/000164117225013237/formdef14a.htm
2 · Reply